Indomethacin Cuts Incidence of Post-ERCP Pancreatitis

Indomethacin Cuts Incidence of Post-ERCP Pancreatitis
Indomethacin Cuts Incidence of Post-ERCP Pancreatitis

(HealthDay News) – For patients who undergo endoscopic retrograde cholangiopancreatography (ERCP), a single dose of rectal indomethacin immediately after the procedure is associated with a significantly reduced incidence of pancreatitis.

B. Joseph Elmunzer, MD, from the University of Michigan Medical Center in Ann Arbor, and colleagues randomly allocated 602 patients at increased risk for post-ERCP pancreatitis to receive a single dose of rectal indomethacin or placebo immediately after the procedure.

The researchers found that 82% of patients had clinical suspicion of sphincter of Oddi dysfunction. Post-ERCP pancreatitis developed in significantly fewer patients in the indomethacin group than the placebo group (9.2 vs. 16.9%). In addition, moderate-to-severe pancreatitis developed in significantly fewer patients in the indomethacin group than the placebo group (4.4 vs. 8.8%).

"Prophylactic rectal indomethacin significantly reduced the incidence and severity of post-ERCP pancreatitis in patients at elevated risk for this complication, particularly in those with a clinical suspicion of sphincter of Oddi dysfunction," the authors write.

Several authors disclosed financial relationships with pharmaceutical, medical, and biotechnology companies.

Full Text (subscription or payment may be required)